Pre-transplant elevations of interleukin-12 and interleukin-10 are associated with acute rejection after renal transplantation

Clinical Transplantation
Jason T FitzgeraldRichard V Perez

Abstract

Methods for predicting patients at higher risk for rejection before transplantation may help improve outcomes. We hypothesized that pre-transplant elevations of serum interleukin-12 (IL-12), a pro-inflammatory cytokine, would predict acute rejection, while pre-transplant IL-10, an immunoregulatory cytokine, would be down-regulated in patients subsequently experiencing acute rejection. Thirty patients experiencing acute rejection after cadaveric renal allograft transplantation and a control group of 30 patients, undergoing the same procedure but without the occurrence of rejection, were identified. Serum samples taken before transplantation from each patient were then analyzed quantitatively for IL-12 and IL-10 using ELISA assays. The mean pre-transplant serum IL-12 level was higher in patients who subsequently underwent acute rejection vs. those who did not (181 +/- 143 pg/mL vs. 81.2 +/- 71.5 pg/mL, respectively, p = 0.007). Unexpectedly, pre-transplant serum IL-10 levels were also elevated in patients who underwent rejection (559 +/- 293 pg/mL vs. 332 +/- 163 pg/mL, respectively, p = 0.002). Multivariate analysis demonstrated that elevations of IL-12 and IL-10 were independent risk factors for rejection when adjusted for conf...Continue Reading

References

Apr 3, 1997·The New England Journal of Medicine·P M RidkerC H Hennekens
Apr 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jeffrey C FinkMatthew R Weir
Dec 31, 2002·Microbes and Infection·Wayne M Yokoyama, Anthony A Scalzo

❮ Previous
Next ❯

Citations

Nov 1, 2008·Expert Opinion on Medical Diagnostics·Olaf Boenisch, Anil Chandraker
Jul 13, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Lavjay ButaniRichard V Perez
Aug 17, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Vijayan SureshEdward Kaminski
Jul 7, 2016·Mediators of Inflammation·Dorota KamińskaMarian Klinger
Jan 31, 2019·Cardiovascular Research·Dakshnapriya BalasubbramanianBrett M Mitchell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.